Vildagliptin
- Generic Name
- Vildagliptin
- Brand Names
- Galvus, Jalra, Xiliarx
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25N3O2
- CAS Number
- 274901-16-5
- Unique Ingredient Identifier
- I6B4B2U96P
- Background
Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependen...
- Indication
Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults. As monotherapy, vildagliptin is indicated in adults inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. It is also indicated as dual therapy in combination with metformin, a sulphonylurea, or a thi...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)
- Conditions
- Interventions
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 349
- Registration Number
- NCT00765830
- Locations
- 🇪🇸
Hospital de la Ribera, Alzira, Spain
🇪🇸Hospital San Pedro de Alcantara, Caceres, Spain
🇪🇸Clinica Mediterranea de Neurociencias, Alicante, Spain
Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 63
- Registration Number
- NCT00651105
- Locations
- 🇩🇪
Novartis Investigator Site, Berlin, Germany
Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 525
- Registration Number
- NCT00646542
Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 22
- Registration Number
- NCT00633997
- Locations
- 🇺🇸
Novartis Investigator Site, Baltimore, Maryland, United States
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 148
- Registration Number
- NCT00616811
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Anasazi Internal Medicine, Phoenix, Arizona, United States
Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients
- First Posted Date
- 2007-12-13
- Last Posted Date
- 2012-05-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 29
- Registration Number
- NCT00572650
- Locations
- 🇩🇪
Novartis Investigator Site, Kiel, Germany
Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 96
- Registration Number
- NCT00567047
- Locations
- 🇩🇪
Novartis Investigator Site, Kiel, Germany
Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
- Conditions
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novartis
- Registration Number
- NCT00494884
- Locations
- 🇩🇪
Novartis Investigative Site, Bochum, Germany
Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 914
- Registration Number
- NCT00396357
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
🇩🇪Novartis Investigative Site, Multiple Locations, Germany
Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone
- Conditions
- Interventions
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2665
- Registration Number
- NCT00396227
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.